Fundraising Fox
/Companies
Sign in

InGel

Cambridge, US · Founded 2022 · 7 known investors

Find your way into InGel

Sign up to see every warm intro you have to InGel

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the InGel team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

InGel Therapeutics develops engineered cell therapies for complex retinal degenerative diseases, combining retinal precursor cells with a biomimetic hyaluronic acid and gelatin hydrogel delivery matrix that mimics the human vitreous. The company also runs Regenesis, a target discovery platform using single-cell proteomics to identify neuroprotective pathways in the eye.

BiotechDeep TechHealthtech

Founders & leadership

InGel was founded in 2022 by Patrick Jiang, Pierre Colombe Dromel, and Deepti Singh.

PJPatrick Jiang
Patrick JiangCEO & Co-founderCEO & Co-founder at InGel Website
PCPierre Colombe Dromel
Pierre Colombe DromelChief Technology Officer & Co-founderChief Technology Officer & Co-founder at InGel Website
DSDeepti Singh
Deepti SinghChief Scientific Officer & Co-founderDeepti Singh holds a Ph.D. in biomaterials-based tissue regeneration and trained at Yale and Harvard University. She is Co-founder and Chief Scientific Officer of InGel Therapeutics, which develops engineered cell therapies for retinal degenerative diseases using biomimetic hydrogel delivery systems.
MS
Myron SpectorNamed on SEC filing
MY
Michael YoungNamed on SEC filing

Investors · 7

Gaingelslisted by GaingelsNew York · $200K – $500K

How we know: gaingels.com · Not right? Tell us

Icebook Investments Corp.listed by Icebook Investments Corp.Calgary

How we know: Icebook Investments Corp.'s portfolio page · Not right? Tell us

MassVentureslisted by MassVenturesWaltham · $250K – $500K
Service Provider Capitallisted by Service Provider CapitalVail

How we know: the VCSheet dataset · Not right? Tell us

The Venture Collectivelisted by The Venture CollectiveMiami Beach · $100K – $500K

How we know: The Venture Collective's portfolio page · the VCSheet dataset · Not right? Tell us

ZAKA VClisted by ZAKA VCSan Francisco

How we know: ZAKA VC's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$350K disclosed across 1 round · 2022

▶$350KraisedAug 2022 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Myron SpectorDirector
  • Pierre Colombe DromelExecutive Officer, Director
  • Deepti SinghDirector
  • Michael YoungDirector
Offering amount
$1M
Amount sold
$350K
First sale
Jul 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does InGel do?
InGel Therapeutics develops engineered cell therapies for complex retinal degenerative diseases, combining retinal precursor cells with a biomimetic hyaluronic acid and gelatin hydrogel delivery matrix that mimics the human vitreous. The company also runs Regenesis, a target discovery platform using single-cell proteomics to identify neuroprotective pathways in the eye.
Who founded InGel?
InGel was founded by Patrick Jiang, Pierre Colombe Dromel, Deepti Singh in 2022.
Who are InGel's investors?
InGel's investors include Bacchus Venture Capital, Gaingels, Icebook Investments Corp., MassVentures, Service Provider Capital, The Venture Collective, ZAKA VC.
How much funding has InGel raised?
InGel has disclosed $350K raised across 1 round.
Where is InGel headquartered?
InGel is headquartered in Cambridge, US.